Clinical Trial Update: OSE2101 Versus Chemotherapy in HLA-A2 Positive Patients With Advanced NSCLC After Immune Checkpoint Inhibitor Failure [Phase 3]

View source ↗

Summary

Phase 3 trial comparing OSE2101 to chemotherapy in HLA-A2 positive advanced NSCLC after immune checkpoint inhibitor failure was terminated; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Chemotherapy (chemotherapy)
• OSE2101

Snippet

Sponsor: OSE Immunotherapeutics | Conditions: Non Small Cell Lung Cancer | Phase 3 | Status: TERMINATED | Results posted: 2024-02-02